Try our mobile app
Screener
Company
Price and
change
Revenue Growth
last / hist
EV /
LTM
EBITDA
(p75)
EV/
Sales
EBITDA LTM
/ Revenue
FCF LTM
/ Revenue
Next GAAP report
Year div-d yield
FCF Yield LTM
67.1%  /
73.1%
28.4x
26.7x
7.2x
25.2%
102.4%
..
0.0%
12.6% 
-2.7%  /
71.4%
>200x
>200x
4.2x
-7.6%
-23.8%
2025-10-29
0.0%
-6.4% 
44.9%  /
69.2%
104.2x
92.9x
11.9x
11.3%
25.6%
2025-10-29
0.0%
2.1% 
46.7%  /
59.4%
36.9x
>200x
0.5x
1.3%
-36.7%
2025-11-12
0.0%
-223.1% 
47.8%  /
47.8%
>200x
>200x
3.2x
-0.4%
2.0%
..
0.0%
0.8% 
28.0%  /
34.8%
>200x
>200x
6.2x
-2.6%
20.4%
2025-11-12
0.0%
3.0% 
11.4%  /
32.9%
8x
27.9x
0.1x
1.3%
-5.5%
2025-11-11
0.0%
-91.9% 
14.1%  /
32.6%
>200x
1.2x
-0x
-7.9%
-12.2%
..
0.0%
-37.1% 
14.5%  /
29.5%
42.2x
48.8x
1.4x
3.3%
-5.5%
..
0.0%
-3.8% 
35.9%  /
25.9%
27x
74x
0.2x
0.6%
-0.6%
2026-02-05
0.0%
-2.1% 
-1.2%  /
23.3%
>200x
>200x
0.7x
-24.8%
-44.1%
..
0.0%
-401.6% 
19.2%  /
19.2%
>200x
>200x
3.3x
-12.4%
-9.9%
..
0.0%
-3.1% 
-2.5%  /
18.0%
>200x
>200x
3.1x
-9.0%
4.5%
2025-11-03
0.0%
1.5% 
16.4%  /
17.7%
41.8x
73.4x
1.7x
4.0%
1.5%
2025-11-04
0.0%
0.9% 
13.4%  /
11.2%
18.9x
21.7x
3.6x
20.0%
0.8%
2025-10-30
0.0%
0.2% 
200.0%  /
6.7%
154.8x
185.9x
3x
1.8%
-2.5%
2026-02-05
0.0%
-0.9% 
1.0%  /
6.5%
11.2x
13.8x
0.3x
2.6%
-4.3%
2025-11-13
3.0%
-12.7% 
0.8%  /
6.2%
20.2x
24.6x
2.9x
14.2%
-1.6%
2025-10-29
0.0%
-0.7% 
9.6%  /
4.1%
19.2x
40.7x
1.1x
5.5%
6.2%
2025-11-04
0.0%
4.6% 
9.5%  /
2.7%
19.4x
17.3x
4.6x
24.2%
23.5%
2025-10-29
1.4%
5.5% 
3.3%  /
2.0%
17x
11.8x
3.1x
18.0%
-4.4%
2025-11-13
1.2%
-1.4% 
0.0%  /
0.0%
10x
>200x
0.8x
7.7%
0.0%
..
12.9%
--- 
0.0%  /
0.0%
51.6x
>200x
14.2x
0.0%
0.0%
..
0.0%
--- 
0.0%  /
0.0%
7.6x
>200x
0.4x
5.3%
-9.3%
2025-11-17
0.0%
-20.0% 
-10.0%  /
-0.2%
>200x
>200x
2x
-11.1%
8.5%
..
0.0%
4.2% 
4.6%  /
-1.0%
>200x
11.9x
0.2x
-2.8%
30.1%
..
0.0%
173.1% 
-2.6%  /
-1.1%
7.8x
7.5x
0.5x
7.0%
0.2%
2025-11-13
2.7%
0.2% 
-15.7%  /
-1.4%
>200x
0.3x
-0x
9.9%
59.2%
..
0.0%
5 179.2% 
-7.1%  /
-1.5%
>200x
8.7x
0.6x
-31.0%
1.3%
2026-02-05
0.0%
45.4% 
0.0%  /
-5.0%
>200x
>200x
0.6x
-27.0%
-14.6%
2025-11-07
0.0%
-10.1% 
-17.4%  /
-19.7%
>200x
125.7x
0.8x
-7.0%
1.4%
2026-02-25
0.0%
1.5% 
-33.3%  /
-33.3%
>200x
>200x
1x
-35.0%
10.0%
..
0.0%
10.5% 
-50.0%  /
-51.1%
>200x
16x
-0.4x
-13.3%
-17.8%
..
0.0%
-44.4% 
Trending screeners:
@electric-vehicles
@saas
@cannabis-players
@china
Latin America
India
Dividends
@REITs
@adtech
@airlines
@artificial-intelligence
@auto-parts
@cloud-computing
@crypto
@cybersecurity
@e-commerce
@edtech
@finance-and-technology
@gaming
@internet-of-things
@oil-refining
@real-estate-tech
@renewable-energy
@vaccine-makers

Reviews

2025-11-04
#reports #PRIM

[Primoris Services](https://eninvs.com/all.php?name=PRIM) (Engineering and Construction) reported for [2025 q3](https://eninvs.com/press_release.php?ticker=PRIM&q=2025 q3&id=895340)
(2025-11-03, After Market Close):

- Revenue +32.1% YoY (vs +20.9% in previous quarter and historical rate +24.8%)
- EBITDA +32% YoY (vs +33.0% in previous quarter and historical rate +26.2%)
- EBITDA margin 7.4% has not changed compared to 7.4% same period last year
- Net Debt decreased by $160 mln over the past reporting period (2.1% of market cap)
- FCF (LTM) +$0.3 bln (positive), 4.3% of market cap
- EV/EBITDA multiple is 15.9x compared to historical level (75th percentile) of 10.9x
- EV/Sales multiple is 1.1x

2025-11-04
#reports #PLTR

[Palantir Technologies](https://eninvs.com/all.php?name=PLTR) (Software provider) reported for 2025 q3
(2025-11-03, After Market Close):

- Revenue +62.7% YoY (vs +48.1% in previous quarter and historical rate +29.0%)
- EBITDA +229.8% YoY (vs +144.2% in previous quarter and historical rate +144.3%)
- EBITDA margin 33.8% increased compared to 16.7% same period last year
- Net Debt decreased by $439 mln over the past reporting period (0.1% of market cap)
- FCF (LTM) +$1.5 bln (positive), 0.3% of market cap
- EV/EBITDA multiple is 476.8x compared to historical level (75th percentile) of 574.5x
- EV/Sales multiple is 108.2x

2025-11-04
#reports #PAY

[Paymentus Holdings, Inc.](https://eninvs.com/all.php?name=PAY) (Information Technology Services) reported for [2025 q3](https://eninvs.com/press_release.php?ticker=PAY&q=2025 q3&id=895332)
(2025-11-03, After Market Close):

- Revenue +34.1% YoY (vs +42.1% in previous quarter and historical rate +34.0%)
- EBITDA +42.9% YoY (vs +36.8% in previous quarter and historical rate +88.3%)
- EBITDA margin 9.6% increased compared to 9.1% same period last year
- Net Debt decreased by $23 mln over the past reporting period (0.6% of market cap)
- FCF (LTM) +$0.1 bln (positive), 2.9% of market cap
- EV/EBITDA multiple is 31.1x compared to historical level (75th percentile) of 51.9x
- EV/Sales multiple is 2.9x

2025-11-04
#reports #ON

[ON Semiconductor](https://eninvs.com/all.php?name=ON) (Semiconductor manufacturer) reported for [2025 q3](https://eninvs.com/press_release.php?ticker=ON&q=2025 q3&id=895330)
(2025-11-03, Before Market Open):

- Revenue -12% YoY (vs -15.3% in previous quarter and historical rate -7.9%)
- EBITDA -32.3% YoY (vs -36.1% in previous quarter and historical rate -19.9%)
- EBITDA margin 26.5% decreased compared to 34.4% same period last year
- Net Debt decreased by $43 mln over the past reporting period (0.3% of market cap)
- FCF (LTM) +$0.5 bln (positive), 2.8% of market cap
- EV/EBITDA multiple is 18.6x compared to historical level (75th percentile) of 13.6x
- EV/Sales multiple is 2.8x

At the opening of the session the share price went down -1.1% vs S&P500 +0.6%
2025-11-04
#reports #OGS

[ONE Gas](https://eninvs.com/all.php?name=OGS) (Gas provider) reported for [2025 q3](https://eninvs.com/press_release.php?ticker=OGS&q=2025 q3&id=895328)
(2025-11-03, After Market Close):

- Revenue +11.5% YoY (vs +19.8% in previous quarter and historical rate +2.2%)
- EBITDA +7.6% YoY (vs +6.3% in previous quarter and historical rate +26.5%)
- EBITDA margin 37.5% decreased compared to 38.8% same period last year
- Net Debt increased by $89 mln over the past reporting period (1.8% of market cap)
- FCF (LTM) -$0.3 bln (negative), 5.5% of market cap
- EV/EBITDA multiple is 21.1x compared to historical level (75th percentile) of 22.6x
- EV/Sales multiple is 6.9x

2025-11-04
#reports #NOVT

[Novanta](https://eninvs.com/all.php?name=NOVT) (Scientific and Technical Instruments) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=192870)
(2025-11-04, Before Market Open):

- Revenue +1.6% YoY (vs +2.1% in previous quarter and historical rate +4.6%)
- EBITDA -19.1% YoY (vs -25.0% in previous quarter and historical rate +2.6%)
- EBITDA margin 15.3% decreased compared to 19.3% same period last year
- Net Debt increased by $12 mln over the past reporting period (0.2% of market cap)
- FCF (LTM) +$0 bln (positive), 0.1% of market cap
- EV/EBITDA multiple is 34.2x compared to historical level (75th percentile) of 41x
- EV/Sales multiple is 5.5x

2025-11-04
#reports #KRYS

[Krystal Biotech](https://eninvs.com/all.php?name=KRYS) (Medicine services provider) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=192896)
(2025-11-03, Before Market Open):

- Revenue +16.7% YoY (vs +162.9% in previous quarter and historical rate +116.0%)
- EBITDA +79.2% YoY (vs +600.0% in previous quarter and historical rate +106.6%)
- EBITDA margin 43.9% increased compared to 28.6% same period last year
- Net Debt decreased by $50 mln over the past reporting period (0.9% of market cap)
- FCF (LTM) +$0.1 bln (positive), 1.6% of market cap
- EV/EBITDA multiple is 24.8x compared to historical level (75th percentile) of 111x
- EV/Sales multiple is 10.8x

At the opening of the session the share price went up +0.1% vs S&P500 +0.6%
2025-11-04
#reports #IRMD

[IRadimed Corporation](https://eninvs.com/all.php?name=IRMD) (Medical Devices) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=192895)
(2025-11-03, Before Market Open):

- Revenue +16.7% YoY (vs +11.1% in previous quarter and historical rate +17.2%)
- EBITDA +16.7% YoY (vs +16.7% in previous quarter and historical rate +23.8%)
- EBITDA margin 33.3% has not changed compared to 33.3% same period last year
- Net Debt decreased by $4 mln over the past reporting period (0.4% of market cap)
- FCF (LTM) +$0 bln (positive), 0.2% of market cap
- EV/EBITDA multiple is 38.9x compared to historical level (75th percentile) of 31.6x
- EV/Sales multiple is 12.7x

At the opening of the session the share price went up +7.1% vs S&P500 +0.6%
2025-11-04
#reports #INSP

[Inspire Medical Systems](https://eninvs.com/all.php?name=INSP) (Medical device developer) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=192894)
(2025-11-03, After Market Close):

- Revenue +10.8% YoY (vs +10.7% in previous quarter and historical rate +39.0%)
- EBITDA -31.3% YoY (vs -114.3% in previous quarter)
- EBITDA margin 4.9% decreased compared to 7.9% same period last year
- Net Debt decreased by $7 mln over the past reporting period (0.3% of market cap)
- FCF (LTM) -$0 bln (negative), 2.1% of market cap
- EV/EBITDA multiple is 52.3x compared to historical level (75th percentile) of 294.8x
- EV/Sales multiple is 2.4x

2025-11-04
#reports #III

[Information Services Group](https://eninvs.com/all.php?name=III) (Information Technology Services) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=192893)
(2025-11-03, Before Market Open):

- Revenue +1.6% YoY (vs -3.1% in previous quarter and historical rate -4.8%)
- EBITDA 0% YoY (vs +20.0% in previous quarter)
- EBITDA margin 8.1% decreased compared to 8.2% same period last year
- Net Debt increased by $3 mln over the past reporting period (1.0% of market cap)
- FCF (LTM) +$0 bln (positive), 1.7% of market cap
- EV/EBITDA multiple is 20.8x compared to historical level (75th percentile) of 17.9x
- EV/Sales multiple is 1.4x

At the opening of the session the share price went up +6.9% vs S&P500 +0.6%
2025-11-04
#reports #IDXX

[IDEXX Laboratories](https://eninvs.com/all.php?name=IDXX) (Products and services for veterinary medicine producer) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=192892)
(2025-11-03, Before Market Open):

- Revenue +13.2% YoY (vs +10.5% in previous quarter and historical rate +7.6%)
- EBITDA +15.1% YoY (vs +38.7% in previous quarter and historical rate +14.2%)
- EBITDA margin 35.1% increased compared to 34.5% same period last year
- EV/EBITDA multiple is 41.5x compared to historical level (75th percentile) of 38.3x
- EV/Sales multiple is 14.2x

At the opening of the session the share price went up +10.1% vs S&P500 +0.6%
2025-11-04
#reports #ICHR

[Ichor](https://eninvs.com/all.php?name=ICHR) (Semiconductor Equipment and Materials) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=192891)
(2025-11-03, After Market Close):

- Revenue +13.3% YoY (vs +18.2% in previous quarter and historical rate -5.5%)
- EBITDA -271.4% YoY (vs -50.0% in previous quarter and historical rate -22.7%)
- EBITDA margin -5.0% decreased compared to 3.3% same period last year
- Net Debt decreased by $2 mln over the past reporting period (0.3% of market cap)
- FCF (LTM) -$0 bln (negative), 2.3% of market cap
- EV/EBITDA multiple is 165.1x compared to historical level (75th percentile) of 112.3x
- EV/Sales multiple is 0.9x

2025-11-04
#reports #HSII

[Heidrick & Struggles International](https://eninvs.com/all.php?name=HSII) (Executive recruitment specialist) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=192889)
(2025-11-03, After Market Close):

- Revenue +15.9% YoY (vs +13.8% in previous quarter and historical rate +18.9%)
- EBITDA -20.8% YoY (vs +2400.0% in previous quarter and historical rate -5.1%)
- EBITDA margin 5.8% decreased compared to 8.5% same period last year
- Net Debt decreased by $133 mln over the past reporting period (11.0% of market cap)
- FCF (LTM) +$0.1 bln (positive), 5.7% of market cap
- EV/EBITDA multiple is 9.4x compared to historical level (75th percentile) of 9.3x
- EV/Sales multiple is 0.4x

2025-11-04
#reports #HOLX

[Hologic](https://eninvs.com/all.php?name=HOLX) (Medical equipment provider) reported for 2025 q3
(2025-11-03, After Market Close):

- Revenue +6.3% YoY (vs +1.3% in previous quarter and historical rate -4.2%)
- EBITDA +4.2% YoY (vs -3.1% in previous quarter and historical rate -7.3%)
- EBITDA margin 28.2% decreased compared to 28.7% same period last year
- Net Debt decreased by $325 mln over the past reporting period (2.0% of market cap)
- FCF (LTM) +$0.1 bln (positive), 0.5% of market cap
- EV/EBITDA multiple is 20x compared to historical level (75th percentile) of 19.4x
- EV/Sales multiple is 4.1x

2025-11-04
#reports #HLIT

[Harmonic](https://eninvs.com/all.php?name=HLIT) (Communication Equipment) reported for [2025 q3](https://eninvs.com/press_release.php?ticker=HLIT&q=2025 q3&id=895297)
(2025-11-03, After Market Close):

- Revenue -27.6% YoY (vs -0.7% in previous quarter and historical rate +2.5%)
- EBITDA -65.8% YoY (vs +600.0% in previous quarter and historical rate +27.3%)
- EBITDA margin 9.2% decreased compared to 19.4% same period last year
- Net Debt decreased by $4 mln over the past reporting period (0.3% of market cap)
- FCF (LTM) +$0.1 bln (positive), 5.5% of market cap
- EV/EBITDA multiple is 13.7x compared to historical level (75th percentile) of 38.9x
- EV/Sales multiple is 1.9x

2025-11-04
#reports #HALO

[Halozyme Therapeutics](https://eninvs.com/all.php?name=HALO) (Medicines provider) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=192888)
(2025-11-03, After Market Close):

- Revenue +22.1% YoY (vs +41.1% in previous quarter and historical rate +49.5%)
- EBITDA +33.1% YoY (vs +69.7% in previous quarter and historical rate +37.5%)
- EBITDA margin 62.4% increased compared to 57.2% same period last year
- Net Debt decreased by $152 mln over the past reporting period (1.9% of market cap)
- FCF (LTM) -$0.2 bln (negative), 2.5% of market cap
- EV/EBITDA multiple is 11.8x compared to historical level (75th percentile) of 34.3x
- EV/Sales multiple is 4.6x

2025-11-04
#reports #FRPT

[Freshpet](https://eninvs.com/all.php?name=FRPT) (Animal food manufacturer) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=192885)
(2025-11-03, Before Market Open):

- Revenue +14.2% YoY (vs +12.8% in previous quarter and historical rate +26.1%)
- EBITDA +37.1% YoY (vs +153.8% in previous quarter and historical rate +110.0%)
- EBITDA margin 16.6% increased compared to 13.8% same period last year
- Net Debt decreased by $31 mln over the past reporting period (1.1% of market cap)
- FCF (LTM) -$0.1 bln (negative), 3.7% of market cap
- EV/EBITDA multiple is 26.2x compared to historical level (75th percentile) of 157.4x
- EV/Sales multiple is 2.7x

At the opening of the session the share price went up +8.3% vs S&P500 +0.6%
2025-11-04
#reports #FN

[Fabrinet](https://eninvs.com/all.php?name=FN) (Electronic Components) reported for [2025 q3](https://eninvs.com/press_release.php?ticker=FN&q=2025 q3&id=895285)
(2025-11-03, After Market Close):

- Revenue +21.6% YoY (vs +20.8% in previous quarter and historical rate +15.0%)
- EBITDA +21.3% YoY (vs +18.6% in previous quarter and historical rate +18.1%)
- EBITDA margin 11.0% has not changed compared to 11.1% same period last year
- Net Debt decreased by $35 mln over the past reporting period (0.2% of market cap)
- FCF (LTM) +$0.1 bln (positive), 0.4% of market cap
- EV/EBITDA multiple is 37.9x compared to historical level (75th percentile) of 24.2x
- EV/Sales multiple is 4.1x

2025-11-04
#reports #EXAS

[Exact Sciences](https://eninvs.com/all.php?name=EXAS) (Cancer test manufacturer) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=192884)
(2025-11-03, After Market Close):

- Revenue +20% YoY (vs +16.0% in previous quarter and historical rate +15.4%)
- Net Debt decreased by $146 mln over the past reporting period (1.2% of market cap)
- FCF (LTM) +$0.2 bln (positive), 1.8% of market cap
- EV/Sales multiple is 4.6x

2025-11-04
#reports #ENSG

[Ensign](https://eninvs.com/all.php?name=ENSG) (Provides patient care/rehabilitation services) reported for [2025 q3](https://eninvs.com/press_release.php?ticker=ENSG&q=2025 q3&id=895277)
(2025-11-03, After Market Close):

- Revenue +19.8% YoY (vs -33.0% in previous quarter and historical rate +36.8%)
- EBITDA -3.1% YoY (vs +32.7% in previous quarter and historical rate +19.5%)
- EBITDA margin 9.5% decreased compared to 11.7% same period last year
- Net Debt increased by $30 mln over the past reporting period (0.3% of market cap)
- FCF (LTM) +$0.1 bln (positive), 0.5% of market cap
- EV/EBITDA multiple is 17.6x compared to historical level (75th percentile) of 23.8x
- EV/Sales multiple is 1.8x

2025-11-04
#reports #CSTL

[Castle Biosciences](https://eninvs.com/all.php?name=CSTL) (Cancer diseases) reported for [2025 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=192880)
(2025-11-03, After Market Close):

- Revenue -3.5% YoY (vs -1.1% in previous quarter and historical rate +43.7%)
- EBITDA -133.3% YoY (vs +212.5% in previous quarter and historical rate +55.6%)
- EBITDA margin -3.6% decreased compared to 10.5% same period last year
- Net Debt decreased by $3 mln over the past reporting period (0.4% of market cap)
- FCF (LTM) -$0 bln (negative), 3.1% of market cap
- EV/EBITDA multiple is 87.9x compared to historical level (75th percentile) of 134.3x
- EV/Sales multiple is 2.1x